At a cool $1B-plus in upfront, equity and early-stage cash, Regeneron ties a blockbuster R&D partnership knot with RNAi leader Alnylam
Regeneron, the masters of antibody development and cell surface tech, is going inside the cell. And they’ve chosen the RNAi leaders at Alnylam to lead them in — with some very big goals in mind.
The numbers involved in this new, largely preclinical pact are blockbuster proportioned. And that is very rare.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,900+ biopharma pros reading Endpoints daily — and it's free.